Contineum Therapeutics, Inc. Class A Common Stock (CTNM) — Cash Flow Quality Index
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a Cash Flow Quality Index of 0.98x as of June 2023. Operating cash flow of $40.67 Million is below net income of $41.56 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore how well can Contineum Therapeutics, Inc. Class A Com service its debt to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Contineum Therapeutics, Inc. Class A Common Stock Cash Flow Quality Index (2023–2023)
Historical Cash Flow Quality Index for Contineum Therapeutics, Inc. Class A Common Stock across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see Contineum Therapeutics, Inc. Class A Com cash flow conversion.
Annual Cash Flow Quality Index for Contineum Therapeutics, Inc. Class A Common Stock (2023–2023)
Year-by-year earnings quality comparison for Contineum Therapeutics, Inc. Class A Common Stock.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2023 | 0.85x | $19.35 Million | $22.72 Million | — |